Innovative Oncology Focus Peptomyc specializes in developing small protein therapeutics targeting the MYC oncoprotein, a key driver in many cancers including osteosarcoma. This positions the company as a promising partner for oncological drug discovery and collaborations aimed at MYC-related cancer treatments.

Recent Clinical Progress With a Phase 2 trial approved for OMO-103, Peptomyc demonstrates advancing clinical development, creating opportunities to engage with their pipeline for potential clinical collaborations, clinical trial support, or joint research initiatives.

Strong Funding and Leadership Having secured over EUR 11 million in financing and appointing experienced industry leaders, Peptomyc is positioned for growth and innovation, making it attractive for investment, partnership, or service collaborations to accelerate their research and development efforts.

Growth-Driven Expansion As a small but recognized company awarded as the Most Innovative Life Sciences Start-up in 2018, Peptomyc offers opportunities for companies seeking innovative biotech partners for co-developing peptide-based therapeutics or expanding into oncology markets.

Technology and Platform Capabilities Leveraging advanced biotech techniques, Peptomyc’s focus on cell penetrating peptides and mini-protein therapeutics indicates potential sales opportunities in supplying specialized research tools, reagents, or companion diagnostics aligned with their therapeutic development.